AirNexis Therapeutics
AirNexis Therapeutics Raises $200M Series A | Novel COPD Treatment
AirNexis Therapeutics Launches with $200M Series A
AirNexis Therapeutics has emerged from stealth with $200 million in Series A financing to advance a novel therapy for chronic obstructive pulmonary disease (COPD).
The round was led by Frazier Life Sciences with participation from OrbiMed, SR One, Goldman Sachs, Longitude Capital, and Enavate Sciences.
Key Highlights
- One of the largest Series A rounds in biotech
- Novel dual PDE3/4 inhibitor for COPD
- Combines bronchodilation and inflammation reduction
Company Overview
AirNexis Therapeutics is developing a dual PDE3/4 inhibitor that combines bronchodilation with anti-inflammatory effects, potentially offering COPD patients a more effective treatment option.
Company Info
Investors (4)
Share
Related Reports
Wabi Raises $55M at $1.25B Valuation in IVP-Led Funding
Wabi announced $55 million in funding led by IVP at a $1.25 billion valuation, which it said will support continued product development and expansion.
StimCardio Raises $30M Series A for Wearable AF Therapeutic
StimCardio announced the closing of an oversubscribed $30 million Series A led by Metis Medtech, expected to fund the company through its planned NeuroPulse 2 pivotal study and preparation for an FDA De Novo submission.
Casap Raises $56M Series B for AI Agents in Financial Services
Casap raised a $56 million Series B led by Base10 Partners, with Experian and Synchrony participating, to advance its AI agent platform for financial services.
Turn your sales ideas into reality today
Pick a plan and go live today. Change or cancel any time.
Get started